News for AKTX Stock

Akari Therapeutics Releases New CEO Corner Segment Highlighting 2025 Progress and Path to Clinical Transition In 2026 Akari Therapeutics to Present at the 2026 Biotech Showcase Akari Therapeutics Issues 2025 End of Year Letter to Shareholders Akari Therapeutics Initiates GMP Manufacturing of AKTX-101 ADC Program to Support Phase 1 First-in-Human Clinical Trial Akari Therapeutics Releases Virtual Investor “What This Means” Segment Akari Therapeutics Announces $5 Million Financing, Including Concurrent Registered Direct Offering and Private Placement Priced At-Market Akari Therapeutics Highlights Preclinical Data Demonstrating Therapeutic Potential of Lead Candidate, AKTX-101, for Hard-to-Treat K-Ras Mutant Pancreatic Cancer Akari Therapeutics Provides Corporate Update and Highlights its ADC Payload Innovation Expected to Drive Value in New CEO Corner Segment Akari Therapeutics Announces Release of the Next CEO Corner Segment Akari Therapeutics Appoints Biotech Finance Leader, Kameel D. Farag as Interim Chief Financial Officer Akari Therapeutics Presents Promising Immuno-Oncology Data for its Novel Splicing-Targeted ADC Payload Driving Immune Activation, Both as Single Agent and in Combination with Anti-PD1 Checkpoint Inhibitors Akari Therapeutics’ Accepted Abstract Showcasing its Novel Splicing-Targeted ADC Payload Driving Immune Activation Now Available Akari Therapeutics Announces Formation of Scientific Advisory Board and Inaugural Appointment of Renowned Medical Oncologist, Sara A. Hurvitz, MD, FACP Akari Therapeutics Announces Launch of CEO Corner Platform Akari Therapeutics Announces $2.5 Million Registered Direct Offering Akari Therapeutics Files Two New Patents for Immuno-Oncology Mode of Action for Novel ADC Platform Utilizing Spliceosome Modulating Payload PH1 Akari Therapeutics Announces Abstract Accepted for Oral Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting Akari Therapeutics’ Preclinical Data Demonstrates the Potential of its Novel ADC Spliceosome Modulating Payload, PH1 Akari Therapeutics Announces Filing for New Patent for Novel ADC Platform Utilizing Spliceosome Payload PH1 for the Treatment of Cancer Akari Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference Akari Therapeutics to Participate in the Virtual Investor Closing Bell Series Akari Therapeutics to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech Akari Therapeutics Releases Virtual Investor “What This Means” Segment Akari Therapeutics Continues Key Research on its Novel Antibody Drug Conjugate Payload PH1 to Further Demonstrate its Unique Ability to Target Cancers Fueled by Oncogenic Drivers Akari Therapeutics Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference Akari Therapeutics Releases Virtual Investor “What This Means” Segment Highlighting its Recently Granted India Patent Akari Therapeutics Bolsters Global IP Estate for its Novel Antibody Drug Conjugate (ADC) Immuno-Oncology Payload, PH1, with Recent Granting of Patent Protection Across India Akari Therapeutics Releases “Meet the Team” Video Featuring Recently Appointed Mark F. Kubik, Head of Business Development – Oncology Akari Therapeutics to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar Akari Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update Akari Therapeutics Appoints Mark F. Kubik as Head of Business Development - Oncology Akari Therapeutics Releases Welcome Video from Newly Appointed Chief Executive Officer, Abizer Gaslightwala Akari Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update Akari Therapeutics Appoints Biotechnology Industry Leader, Abizer Gaslightwala, as President and Chief Executive Officer Akari Therapeutics Announces $7.6 Million Private Placement Offering Led by Existing Shareholders and Insiders Priced at the Market Under Nasdaq Rules Akari Therapeutics Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference Akari Therapeutics Joins Webull Corporate Connect Service Platform Akari Therapeutics Announces Key Leadership Appointments Akari Therapeutics Appoints Torsten Hombeck, Ph.D. as Chief Financial Officer Akari Therapeutics Regains Full Nasdaq Compliance Akari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak Bio Akari Therapeutics Announces Shareholder Approval in Connection With Peak Bio, Inc. Merger Akari Therapeutics Announces Effectiveness of Form S-4 and General Meeting Date of November 7, 2024 Related to Peak Bio Merger Rob Bazemore Appointed to the Board of Directors of Akari Therapeutics Akari Therapeutics Reports Second Quarter 2024 Financial Results and Recent Highlights Akari Therapeutics Receives Positive and Constructive Pre-IND Feedback from US FDA for PAS-nomacopan in Treatment of Geographic Atrophy Akari Therapeutics Announces Interim CEO Employment Contract Demonstrating Alignment with Shareholders Akari Therapeutics Secures $7.6 Million in Upsized Financing Round Akari Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights Samir R. Patel, M.D. Appointed Interim CEO for Akari Therapeutics Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity Akari Therapeutics to Present PAS-Nomacopan Pre-Clinical Electroretinography (ERG) Data at ARVO 2024 Akari Therapeutics Reports Full-Year 2023 Financial Results and Recent Highlights Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing Akari Therapeutics to Present at Biotech Showcase 2024 Akari Therapeutics Appoints Experienced Life Sciences Entrepreneur Samir R. Patel, M.D. to Board of Directors Akari Therapeutics Presents Poster on Progress in Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development Conference Akari Therapeutics to Present a Poster on Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development Conference Akari Therapeutics Reports First Half 2023 Financial Results and Highlights Akari Therapeutics to Present at Emerging Growth Conference Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing, Company Also Receives $2.5 Million U.K. R&D Tax Credit Akari Therapeutics to Host Key Opinion Leader Webinar on Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA) and the Potential of Nomacopan to Address Significant Unmet Needs Akari Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement Akari Therapeutics Announces Establishment of Boston U.S. Headquarters Office to Support Expanding Operations and Start of Registrational Phase 3 Clinical Trials Akari Therapeutics, Plc Announces ADS Ratio Change Akari Therapeutics Announces the Appointment of Beth-Anne Lang as Senior Vice President, Regulatory Affairs Akari Therapeutics Granted Nomacopan Orphan Drug Designation from the European Commission for Treatment in Hematopoietic Stem Cell Transplantation Akari Therapeutics Appoints Experienced Life Sciences Executive Wendy DiCicco as Interim Chief Financial Officer Akari Therapeutics Provides Updates on Development of Nomacopan in Pediatric and Adult HSCT-TMA Akari Therapeutics Provides Update on Development of Long-Acting PAS-Nomacopan for Treatment of Geographic Atrophy Akari Therapeutics Receives Positive Opinion on Orphan Drug Designation from the European Medicines Agency for Nomacopan for Treatment in Hematopoietic Stem Cell Transplantation Akari Therapeutics Appoints Industry Veteran Wa’el Hashad to Board of Directors Akari Therapeutics to Participate in A.G.P.’s Virtual Healthcare Conference Akari Therapeutics Reports Full-Year 2022 Financial Results and Highlights Akari Therapeutics Granted 180-Day Extension by Nasdaq to Meet Minimum Bid Price Requirement Akari Therapeutics to Host Key Opinion Leader Webinar on Geographic Atrophy and the Potential of Long-Acting PAS-Nomacopan to Address Significant Unmet Needs Akari Therapeutics to Attend ARVO 2023, the Annual Meeting of The Association for Research in Vision and Ophthalmology Akari Therapeutics Announces a Case Study from the Phase 3 Part A Clinical Trial of Nomacopan in Pediatric HSCT-TMA Will Be Presented at The European Society for Blood and Marrow Transplantation (EBMT) 49th Annual Meeting Akari Therapeutics, Plc Announces $4 Million Registered Direct Offering Poland and U.K. Regulatory Authorities – URPL and MHRA – Approve Use of New, Higher-Yielding Manufacturing Process for Nomacopan in Pivotal Clinical Study Propulsion of Asthma Pipeline as Novel and Extensive 95+ Therapies Likely to Enter in the Treatment Domain | DelveInsight Akari Therapeutics Announces Presentation of a Case Study from Phase 3 Part A Clinical Trial of Nomacopan in Pediatric HSCT-TMA as a Late-Breaker at The Transplantation & Cellular Therapy Tandem Meetings Akari Therapeutics Announces Pre-Clinical Development Progress Toward Potential IND on Long-Acting PAS-Nomacopan for Geographic Atrophy (GA) Akari Therapeutics Announces Acceleration of the Phase 3 Clinical Trial of Nomacopan for Treatment of Pediatric HSCT-TMA into Pivotal Part B and Addition of a New Pipeline Program Developing Nomacopan for HSCT-TMA in Adults Paroxysmal Nocturnal Hemoglobinuria Market to Climb Moderately at a CAGR of 7.6% During the Study Period (2019-2032), Assesses DelveInsight Akari Therapeutics to Present at Biotech Showcase™ 2023 Akari Therapeutics to Participate in the Cantor Fitzgerald Medical and Aesthetic Dermatology, Ophthalmology and Medtech/Diagnostic Conference Akari Therapeutics to Participate in the Ophthalmology Day at BTIG Akari Therapeutics Granted FDA Rare Pediatric Disease Designation of Nomacopan for the Treatment of Pediatric HSCT-TMA Akari Therapeutics to Participate in the Jefferies London Healthcare Conference Akari Therapeutics Announces the Appointment of John F. Neylan, III, MD as Executive Vice President, Chief Medical Officer Akari Therapeutics to Participate in the Sidoti November 2022 Virtual Micro-Cap Conference Akari Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification Akari Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Pipeline Progress Akari Therapeutics to Participate in the Cantor Oncology & HemOnc Conference Akari Therapeutics Announces $12.75 Million Registered Direct Offering Akari Therapeutics Narrows Pipeline Focus Akari Therapeutics Announces Positive Results from Recent Pre-Clinical Studies of Investigational PASylated® Nomacopan That Support the Potential to Advance Research Toward IND/IMPD for Clinical Trials in Geographic Atrophy Akari Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Pipeline Progress Akari Therapeutics Announces First Patient to Complete Course of Treatment in the Phase III Part A Clinical Trial of Investigational Nomacopan in Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA) Akari Therapeutics Announces the Appointment of Accomplished Biotech Executive Melissa Bradford-Klug as Chief Operating Officer to Lead Business Development and Company Growth Strategies Akari Therapeutics Presents Results from the CASCADE and CORONET Studies in COVID-19 at the American Thoracic Society (ATS) 2022 Annual Meeting Akari Therapeutics Reports Full Year 2021 Financial Results and Highlights Clinical Progress Akari Therapeutics to Present Results from Compassionate Use of Nomacopan for COVID-19 (CORONET) and Identification of Clinical Deterioration Risk in COVID-19 (CASCADE) at the American Thoracic Society (ATS) 2022 Annual Meeting Akari Therapeutics Announces Publication of Phase II Data of Investigational Nomacopan for the Treatment of Bullous Pemphigoid (BP) in JAMA Dermatology Akari Presents Results from Two Preclinical Development Programs of Long-Acting PAS-Nomacopan in Geographic Atrophy (GA) Dry Age-Related Macular Degeneration and Nomacopan in Experimental Immune-Mediated Conjunctival Disease (EIC) Akari Therapeutics to Present on Two Ongoing Programs Covering Age-Related Macular Degeneration and Diseases of the Surface of the Eye at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting Akari Therapeutics Announces New Data Supporting Use of Drug Candidate Votucalis Targeting Difficult to Treat Pain and Itch Akari Therapeutics, Plc Announces $9.0 Million Registered Direct Offering Akari Therapeutics Appoints Rachelle Jacques as President and Chief Executive Officer Akari Therapeutics Announces New Data Showing A Significant Role for Complement Activation in the Clinical Outcomes of U.S. Army Trauma Patients in Iraq and the Therapeutic Potential of Nomacopan for Treatment of Trauma Akari Therapeutics to Present at BIO CEO & Investor Conference Akari Advances Lung Program with Inhaled Nomacopan Focused on Early Treatment of Severe Exacerbations in Lung Diseases FDA Agrees to Use of New Higher-Yielding Manufacturing Process for Nomacopan in Pivotal Clinical Studies Akari Therapeutics to Present at H.C. Wainwright BioConnect Virtual Conference Akari Therapeutics, Plc Announces $6.0 Million Registered Direct Offering Akari Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Clinical Progress Akari Therapeutics Presents New Data Revealing Potential Mechanism of Action Driving Serious Exacerbations Across Lung Disorders Akari Therapeutics Announces Presentation at Annual Complement-Based Drug Development Summit Akari Therapeutics Announces New Data with Nomacopan from its Surface of the Eye Program Akari Therapeutics to Present at the Cantor Virtual Global Healthcare Conference Akari Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Clinical Progress Akari Therapeutics to Present Its Phase III Plans for Nomacopan in Patients with Bullous Pemphigoid at the 2021 International Pemphigus & Pemphigoid Foundation (IPPF) Scientific Symposium Akari Therapeutics to Present at the H.C. Wainwright Global Investment Conference Akari Therapeutics Announces Private Placement Akari Therapeutics Reports Q1 2021 Financial Results and Highlights Recent Clinical Progress Akari Therapeutics Receives FDA Fast Track Designation for Nomacopan for the Treatment of Bullous Pemphigoid Akari Therapeutics Announces Poster Presentation of Phase II Bullous Pemphigoid Disease and Phase III Trial Design at American Academy of Dermatology Association Virtual Meeting Experience Akari Therapeutics Reports Full Year 2020 Financial Results and Highlights Recent Clinical Progress Akari Therapeutics Announces Initiation of Pivotal Phase III Trial of Nomacopan in Bullous Pemphigoid (BP) Akari Therapeutics Announces a Cooperative Research and Development Agreement (CRADA) with the U.S. Army Institute of Surgical Research (USAISR) for Nomacopan in Trauma Akari Therapeutics Presents New Preclinical Data Highlighting Potential of Long-Acting PASylated Nomacopan to Treat Retinal Diseases, Including Age-Related Macular Degeneration (AMD) and Uveitis Akari Therapeutics Adds Histamine Inhibitor Votucalis to Pipeline to treat Neuropathic Pain and Dermatological Disease Akari Therapeutics to Participate in Two January Virtual Investor Conferences Akari Therapeutics Reports Third Quarter 2020 Financial Results and Highlights Recent Clinical Progress Akari Therapeutics Announces New Clinical Data that Show Long-Term Self-Administered Nomacopan is Well-Tolerated and Substantially Reduces Transfusion Dependence in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Akari Therapeutics Announces Publication in American Journal of Pathology Highlighting Potential of Nomacopan in Treatment of Uveitis and Retinal Disease Akari Therapeutics to Present Phase II Data from Bullous Pemphigoid Trial at European Academy of Dermatology and Venereology (EADV) Virtual Congress October 29 Akari Therapeutics Announces Further Clinical Trial Progress Using Nomacopan to Treat COVID-19 Pneumonia Akari Therapeutics Reports Second Quarter 2020 Financial Results and Highlights Recent Clinical Progress Akari Therapeutics Announces International Clinical Development Program of Nomacopan for the Potential Treatment of COVID-19 Pneumonia Akari Therapeutics Announces Successful End-of-Phase II Meeting With FDA to Initiate Pivotal Phase III Study for Treatment of Bullous Pemphigoid With Nomacopan Akari Therapeutics Enters into a Securities Purchase Agreement for up to $30 Million with Aspire Capital Fund, LLC Akari Therapeutics Receives Positive EMA Opinion on Orphan Designation for Nomacopan for Bullous Pemphigoid Akari Therapeutics Announces Positive Topline Results from Fully Recruited Phase II Study of Nomacopan in Bullous Pemphigoid Patients Akari Therapeutics Announces Appointment of Chief Financial Officer Akari Therapeutics to Participate in STRH Life Sciences Virtual Meeting Series